View Older Stories View More Recent Stories

Sep 15, 2022 07:00AM Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Sep 12, 2022 05:34AM Regeneron (REGN) Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
Sep 12, 2022 05:24AM Regeneron (REGN) Reports ubamatamab and REGN5093 Show Encouraging Anti-tumor Activity
Sep 12, 2022 04:30AM Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM
Sep 12, 2022 02:30AM Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhi
Sep 10, 2022 02:30AM Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors
Sep 9, 2022 10:00AM Regeneron Announces Investor Call and Webcast at ESMO 2022
Sep 8, 2022 11:29AM Regeneron (REGN) Says Dupixent Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
Sep 8, 2022 11:29AM Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
Sep 8, 2022 09:01AM Regeneron (REGN) announces Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD
Sep 8, 2022 09:00AM Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals
Sep 5, 2022 07:29AM Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Sep 4, 2022 06:05PM ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers
Aug 25, 2022 04:05PM Regeneron Announces Investor Conference Presentations
Aug 3, 2022 06:30AM Regeneron Reports Second Quarter 2022 Financial and Operating Results
Aug 3, 2022 06:25AM Regeneron (REGN) Reports REGN5678 Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo
Aug 3, 2022 06:25AM Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRP
Jul 27, 2022 05:14PM Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease
Jul 26, 2022 07:00AM Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation
Jul 14, 2022 12:59AM Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Jul 6, 2022 04:01PM Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022
Jul 1, 2022 07:00AM Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab)
Jun 29, 2022 07:31AM Regeneron (REGN) Announces EYLEA Accepted for FDA Review in Patients with Diabetic Retinopathy
Jun 29, 2022 07:30AM EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review
Jun 24, 2022 07:31AM Intellia Therapeutics (NTLA) and Regeneron (REGN) Report Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001
Jun 24, 2022 07:31AM Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Rema
Jun 24, 2022 07:30AM Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Rema
Jun 7, 2022 04:44PM Regeneron (REGN) Announces FDA Approval of Dupixent for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
Jun 7, 2022 04:44PM FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
Jun 2, 2022 07:31AM Regeneron (REGN) to Purchase of Sanofi's (SNY) Stake in the Regeneron and Sanofi Collaboration on Libtayo
Jun 2, 2022 07:30AM Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Can
May 31, 2022 08:36AM Regeneron (REGN) Completes Checkmate Pharmaceuticals Acquisition
May 31, 2022 08:31AM Regeneron Completes Acquisition of Checkmate Pharmaceuticals
May 31, 2022 01:00AM Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
May 31, 2022 12:59AM FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis
May 23, 2022 05:51AM Regeneron (REGN) Reports Evkeeza Phase 3 Trial Demonstrated 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
May 21, 2022 07:00AM Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
May 20, 2022 03:16PM Regeneron (REGN), Sanofi (SNY) Confirm FDA Approves Dupixent as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
May 20, 2022 03:15PM Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
May 20, 2022 03:15PM FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
May 13, 2022 01:13PM High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair
May 13, 2022 11:52AM High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair
May 4, 2022 06:30AM Regeneron Reports First Quarter 2022 Financial and Operating Results
May 2, 2022 04:15PM Regeneron Announces Investor Conference Presentations
Apr 19, 2022 09:24AM Pre-Open Stock Movers 04/19: Super Micro and American Campus Higher; NETGEAR and Stellantis Lower (more...)
Apr 19, 2022 07:00AM Regeneron (REGN) Acquires Checkmate Pharmaceuticals (CMPI) for $10.50/sh Cash
Apr 19, 2022 07:00AM Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
Apr 19, 2022 07:00AM Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
Apr 19, 2022 07:00AM Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
Apr 14, 2022 07:00AM Regeneron (REGN) Announces FDA Extends Review of Biologics License Application for REGEN-COV
View More Recent Stories View Older Stories